INTERNATIONAL JOURNAL OF CLINICAL, BIOMEDICAL AND HEALTH SCIENCES RESEARCH
2026, Vol 1 Issue 1, pp. 01-06
ISSN:xxxx-xxxx
Open Access. Online

www.ijcbhsr.com/

Early Biomarkers of Metabolic Disorders

Dr. Aarav Mehta

Assistant Professor, Department of Environmental Science, Sunrise Institute of Higher Studies, Ahmedabad, Gujarat, India.

International Journal of Clinical, Biomedical and Health Sciences Research

vol 1, Issue1, (2026).

Received: Jan 14, 2026.
Accepted: April 24, 2026.
Published: June 4, 2026.

ABSTRACT:
Metabolic disorders develop through interacting abnormalities in glucose regulation, lipid handling, adipose tissue function, hepatic metabolism, inflammation, and vascular physiology. Biomarkers may identify risk before overt disease, but their clinical value depends on analytical reliability, prospective prediction, and evidence that the result changes management. This review distinguishes established screening markers from emerging candidates for early metabolic dysfunction. Routine measures such as waist circumference, blood pressure, fasting plasma glucose, glycated haemoglobin, triglycerides, and high-density lipoprotein cholesterol remain central because they are standardized, inexpensive, and linked to outcomes. Fasting insulin, HOMA-IR, liver enzymes, high-sensitivity C-reactive protein, adipokines, metabolomic signatures, and continuous glucose metrics may reveal earlier biology, yet many lack universal thresholds or incremental clinical utility. A tiered strategy should begin with phenotype and validated laboratory tests, then reserve novel biomarkers for selected clinical or research contexts. Biomarkers support, but do not replace, clinical assessment.

Keywords: metabolic disorders; early biomarkers; insulin resistance; prediabetes; dyslipidaemia; metabolic syndrome; adipokines; metabolomics

1 Introduction

Metabolic disorders include prediabetes and type 2 diabetes, metabolic syndrome, dyslipidaemia, metabolic dysfunction-associated steatotic liver disease, and related cardiometabolic conditions. These disorders often progress silently while compensatory mechanisms maintain apparently normal values. Early detection aims to identify susceptibility or subclinical dysfunction at a stage when preventive action is possible. A biomarker may be a measured molecule, physiologic variable, imaging feature, or composite score that reflects exposure, biological response, disease state, or prognosis.

The distinction between risk factor and biomarker is practical rather than absolute. Waist circumference, blood pressure, glucose, and lipids are both clinical risk factors and measurable biological indicators. The metabolic syndrome framework uses a cluster of abdominal obesity, raised triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose to identify cardiometabolic risk [1,2].

© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Diabetes screening relies on fasting plasma glucose, a 2-hour oral glucose tolerance test, or HbA1c, with confirmation when required [3,4].

This article reviews establisxhed and emerging biomarkers, describes validation requirements, compares specimen and interpretation issues, and proposes a tiered assessment framework. It is an academic review rather than a diagnostic protocol. Reference intervals and decisions must follow current guidelines, validated laboratory methods, patient context, and professional clinical judgment.

2 Conceptual framework

A useful early biomarker should be biologically plausible, reproducible, sensitive to meaningful change, and additive to readily available information. Analytical validity asks whether the assay accurately and precisely measures its target. Clinical validity asks whether the marker predicts the relevant disorder or outcome. Clinical utility asks whether using it improves decisions or health outcomes. Many exploratory markers show association but fail to add discrimination, calibration, reclassification, or actionability beyond age, adiposity, blood pressure, glucose, and lipids [5].




Figure 1 Tiered framework for evaluating early metabolic biomarkers

Source: Author-generated framework based on clinical guideline and biomarker-validation principles.

2.1 Stages of metabolic dysfunction

Insulin resistance can precede persistent hyperglycaemia. Pancreatic beta cells may initially compensate by increasing insulin secretion, while hepatic lipid accumulation and atherogenic dyslipidaemia develop in parallel. With progressive dysfunction, fasting or post-challenge glucose and HbA1c rise, followed by microvascular and macrovascular injury. The sequence varies between individuals, and a single sample cannot define a universal trajectory.

The best marker depends on the target stage. Fasting glucose and HbA1c detect dysglycaemia but may not capture early postprandial abnormalities. The oral glucose tolerance test can identify impaired glucose tolerance that fasting testing misses. Triglycerides, HDL cholesterol, waist circumference, and blood pressure capture related risk domains. Albuminuria, estimated glomerular filtration rate, and organ-specific markers are more relevant to complications than to the earliest metabolic shift.

2.2 Preanalytical and biological variation

Food intake, exercise, acute illness, sleep, medication, menstrual state, time of day, and sample handling can affect biomarker values. HbA1c interpretation may be altered by conditions affecting red-cell turnover or haemoglobin. Fasting insulin assays are not fully harmonized, limiting universal HOMA-IR thresholds. Liver enzymes may remain normal despite steatotic liver disease. Repeated measurement and integration with clinical context reduce misclassification [3,4].

3 Established and emerging biomarkers

Table 1 Biomarkers relevant to early metabolic dysfunction

Marker	Biological domain	Established use	Important limitation
Fasting glucose HbA1c and OGTT	Glycaemic regulation	Validated screening and diagnostic criteria	Discordance, biological variation and test-specific confounders
Waist blood pressure triglycerides and HDL-C	Adiposity and cardiometabolic risk	Metabolic syndrome and global risk assessment	Clusters risk but does not define one disease mechanism
Fasting insulin and HOMA-IR	Insulin resistance	Research and selected specialist assessment	Assay variability and no universal clinical threshold
ALT GGT and fibrosis scores	Hepatic metabolic injury	Case finding and fibrosis risk stratification	Normal enzymes do not exclude liver disease
CRP adipokines and metabolomics	Inflammation and systemic metabolism	Risk research and experimental stratification	Nonspecificity, cost and limited incremental utility

3.1 Glycaemic and insulin resistance markers

HbA1c reflects average glycaemic exposure over approximately two to three months, while fasting plasma glucose reflects a single fasting state. The 2-hour oral glucose tolerance test challenges glucose regulation and can reveal impaired tolerance. ADA criteria identify prediabetes using HbA1c 5.7–6.4%, fasting plasma glucose 100–125 mg/dL, or 2-hour glucose 140–199 mg/dL; diagnosis requires guideline-consistent confirmation and interpretation [3,4].

3.2 Lipid hepatic and inflammatory markers

Raised triglycerides and reduced HDL cholesterol are established components of metabolic syndrome. ApoB and non-HDL cholesterol can better reflect the number or cholesterol content of atherogenic particles in selected contexts. Alanine aminotransferase, gamma-glutamyl transferase, and fibrosis scores may suggest hepatic metabolic injury but are not sufficiently sensitive to exclude steatotic liver disease. High-sensitivity C-reactive protein reflects systemic inflammation but is nonspecific and varies with infection and other conditions.

Adiponectin, leptin, fetuin-A, branched-chain amino acids, acylcarnitines, ceramides, microRNAs, and multi-metabolite panels are active research areas. Lower adiponectin and altered amino-acid or lipid signatures can precede diabetes in cohorts, but assay platforms, thresholds, population transferability, and incremental value remain unsettled. These markers should not be presented as routine diagnostic tests without validated clinical pathways [6–9].

3.3 Digital and dynamic biomarkers

Continuous glucose monitoring can describe glycaemic variability, time above range, and postprandial responses. Wearables may add activity, sleep, heart-rate, or circadian information. These dynamic measures may reveal physiology missed by occasional blood tests, but normative definitions in people without diabetes, device error, behavioural confounding, data privacy, and evidence of improved outcomes require further study.

4 Methodology and clinical translation

Biomarker studies require prospective cohorts, representative populations, standardized specimens, blinded outcome assessment, and external validation. Models should compare new markers against an appropriate clinical baseline and report calibration as well as discrimination. Multiple testing, overfitting, batch effects, missing data, and spectrum bias must be addressed. A statistically significant association does not prove useful screening. Decision-curve analysis and impact studies can test whether classification changes lead to net clinical benefit.

Table 2 Criteria for evaluating an early metabolic biomarker

Domain	Key question	Preferred evidence	Translation requirement
Analytical validity	Is measurement accurate and reproducible?	Precision, bias, stability and harmonization studies	Quality-controlled assay and reporting standard
Clinical validity	Does it predict a defined outcome?	Prospective cohorts and external validation	Calibration across relevant populations
Incremental value	Does it improve established models?	Discrimination, reclassification and decision analysis	Clinically meaningful gain, not association alone
Clinical utility	Does use improve decisions or outcomes?	Impact studies and pragmatic trials	Actionable pathway with net benefit
Equity and feasibility	Who may be missed or harmed?	Subgroup validation and implementation research	Affordable access and transparent limitations




Figure 2 Conceptual biomarker trajectories during metabolic progression

The curves are conceptual, not patient data or diagnostic cut-offs. They illustrate that compensatory, glycaemic, and organ-injury signals may peak at different stages.

4.1 Interpretation

No single biomarker captures the entire metabolic system. Composite approaches can improve prediction but also increase cost, missingness, and opacity. The most defensible sequence is tiered: assess risk context and phenotype; use validated glucose, lipid, blood-pressure, and anthropometric measures; investigate organ-specific abnormalities when indicated; and apply emerging biomarkers within well-defined studies or specialist pathways. Results near decision limits often warrant confirmation.

5 Clinical implications and conclusion

Screening programmes should prioritize tests with standardized methods, established thresholds, feasible follow-up, and proven links to prevention. Laboratories should report units, methods, reference information, and relevant limitations. Researchers should pre-register analyses, preserve specimens appropriately, publish negative validation studies, and evaluate performance across sex, age, ethnicity, body composition, and comorbidity. Equity matters because biomarker algorithms can perform poorly in underrepresented groups.

Patients should not be labelled or treated on the basis of an experimental biomarker alone. Biomarker results are most useful when they trigger evidence-based confirmation, risk communication, and appropriate preventive or clinical care. Emerging omics and sensor data are promising, but clinical adoption should follow—not precede—demonstration of validity and utility.

6 Conclusion

Early metabolic dysfunction can be detected through a combination of phenotype, routine laboratory measures, and, in selected contexts, emerging biomarkers. HbA1c, fasting and post-challenge glucose, triglycerides, HDL cholesterol, waist circumference, and blood pressure remain the practical foundation. Insulin resistance indices, inflammatory markers, adipokines, metabolomics, and digital signals may refine risk, but limitations in standardization and actionability remain. The goal is not maximum testing; it is timely, accurate, and equitable identification of people who benefit from established preventive evaluation and care.

References

[1] S. M. Grundy et al., "Diagnosis and management of the metabolic syndrome," Circulation, 112(17), 2735–2752 (2005). https://doi.org/10.1161/CIRCULATIONAHA.105.169404

[2] K. G. M. M. Alberti et al., "Harmonizing the metabolic syndrome," Circulation, 120(16), 1640–1645 (2009). https://doi.org/10.1161/CIRCULATIONAHA.109.192644

[3] American Diabetes Association Professional Practice Committee, "Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026," Diabetes Care, 49(Suppl. 1), S27–S49 (2026). https://doi.org/10.2337/dc26-S002

[4] National Institute of Diabetes and Digestive and Kidney Diseases, "Diabetes Tests and Diagnosis," 2025. https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis

[5] M. S. Pepe et al., "Pivotal evaluation of the accuracy of a biomarker used for classification or prediction," Journal of the National Cancer Institute, 100(20), 1432–1438 (2008). https://doi.org/10.1093/jnci/djn326

[6] A. S. Y. Lee et al., "Branched-chain amino acids and incident diabetes: A systematic review and meta-analysis," Nutrition Reviews, 74(9), 534–548 (2016). https://doi.org/10.1093/nutrit/nuw017

[7] T. J. Wang et al., "Metabolite profiles and the risk of developing diabetes," Nature Medicine, 17, 448–453 (2011). https://doi.org/10.1038/nm.2307

[8] C. Herder et al., "Biomarkers of subclinical inflammation and risk of type 2 diabetes," Diabetes Metabolism Research and Reviews, 27(5), 444–457 (2011). https://doi.org/10.1002/dmrr.1215

[9] N. Stefan and H.-U. Haring, "The role of hepatokines in metabolism," Nature Reviews Endocrinology, 9, 144–152 (2013). https://doi.org/10.1038/nrendo.2012.258

[10] A. J. Sanyal et al., "Prospective study of outcomes in adults with nonalcoholic fatty liver disease," New England Journal of Medicine, 385, 1559–1569 (2021). https://doi.org/10.1056/NEJMoa2029349

[11] J. B. Meigs et al., "Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus," JAMA, 291(16), 1978–1986 (2004). https://doi.org/10.1001/jama.291.16.1978

[12] World Health Organization, Classification of Diabetes Mellitus. Geneva: WHO, 2019. https://www.who.int/publications/i/item/classification-of-diabetes-mellitus